William L. Greene, MD

Chief Executive Officer

Dr. Greene has served as Chief Executive Officer and a Director of Iconic Therapeutics since 2014. Dr. Greene joined Iconic from MPM Capital LLC, where he served as Managing Director and a member of the firm’s Investment Committee, leading investments and serving on Boards of Directors of emerging biopharmaceutical and medical device companies. His experience included Alnara (acquired by Eli Lilly:LLY), Alsius (Acquired, Zoll), Barrier Therapeutics (BTRX), Cotherix (CTRX), Idun Pharmaceuticals (acquired by Pfizer:PFE), and Intercell AG (ICLL, Vienna Stock Exchange).

Previously, Dr. Greene was a Senior Clinical Scientist and Epidemiologist at Genentech, Inc., with responsibility for clinical strategy, trial design and execution, and regulatory interactions in several therapeutic areas at all stages of development. While at Genentech, Dr. Greene led the early clinical development of Lucentis® among other products. Prior to Genentech, Dr. Greene was at Yale Medical School where he was a Resident in Internal Medicine and Diagnostic Radiology. He has been an Assistant Clinical Professor of Medicine at UCSF, active on the teaching staff of San Francisco General Hospital.

Dr. Greene is a co-founder of and Senior Advisor to Pear Therapeutics. His passion for using biotechnology to address significant unmet human needs extends to global health. He is an advisor to the Bill and Melinda Gates Foundation and is Chairman of the Investment Committee and on the Board of Directors of the Global Health Investment Fund, a pioneering initiative supported by the Foundation that brings together investors, philanthropists and industry to forge creative solutions to bring the fruits of biotechnology to the underserved around the world.

Dr. Greene received a B.A. degree from Wesleyan University and an M.D. degree from UCSF. Dr. Greene is a member of the American College of Physicians, was a Robert Wood Johnson Clinical Scholar at Yale in clinical epidemiology and a Howard Hughes Medical Institute Research Scholar at the NIH in neurobiology.

Brandon Smith

Chief Operating Officer

Mr. Smith has more than 15 years of experience leading strategy and corporate development functions for public biopharmaceutical companies. He joined Iconic from Impax Laboratories, Inc., where he served as Senior Vice President of Corporate Development and Strategy leading a wide range of functions including business development, licensing, alliance management, deal integration and portfolio management.

Previously, Mr. Smith was an Executive Director at Amgen, Inc., where he led the business case team for Amgen’s entry into biosimilars. Subsequently, he helped form the separate biosimilars business unit responsible for developing and partnering multiple active biosimilars programs. Mr. Smith also served in multiple roles of increasing responsibility at Amgen in Operations Strategy and Corporate Strategy and M&A. Prior to Amgen, Mr. Smith was a Project Leader at The Boston Consulting Group. He also was a Production Engineer and Plant Supervisor at BASF Corporation. Mr. Smith received a B.S. in chemical engineering from the University of Michigan and an M.B.A. from the McCombs School of Business at the University of Texas at Austin.

Gabriela Burian, MD, MPH

Chief Medical Officer

Dr. Burian has more than 15 years of clinical research and development experience focused on retinal disease, with extensive practice in designing, planning and executing global clinical programs. Dr. Burian joined Novartis Pharma in 2005 as Clinical Research Scientist and later held various leadership and management positions including Global Program Medical Director. She was also responsible for clinical development strategies across multiple retinal indications, including age-related macular degeneration, diabetic macular edema (DME), retinal vein occlusion (RVO) and pathologic myopia (PM). She successfully led the global (ex-U.S.) regulatory interactions and approvals of Lucentis® for DME, RVO and PM indications in more than 100 countries.

Most recently, Dr. Burian served as the Ophthalmology Early Program Leader at F. Hoffmann-La Roche, where she was responsible for establishing the translational medicine group and leading early clinical development strategy. Dr. Burian received an M.D. from Victor Babes University of Medicine and Pharmacy in Romania, and a Master’s in Public Health in epidemiology from Rollins School of Public Health at Emory University. After completing her graduate work, Dr. Burian was a Clinical Research Manager and member of the faculty in the Ophthalmology Department at Emory University.

Scott Geyer

Chief Technology Officer

Scott Geyer has more than 35 years of experience in biopharma and protein manufacturing. He joined Iconic from Bavarian Nordic Inc, where he was Vice President of CMC. Previously he was Vice President of CMC Development and Manufacturing at Ambrx Inc. Other positions he has held include Senior Vice President of Manufacturing at CytRx Corporation; Vice President, Technical Operations, at Cerimon Pharmaceuticals, Inc; Vice President, Technical Operations, at Xencor, Inc.; Senior Vice President of Product Development at Onyx Pharmaceuticals; Vice President of Technical Development at Protein Design Labs Inc.; and Executive Director, Process Development at Serono. He started his career as a scientist at Damon Biotech and Smith Kline & French Laboratories. Mr. Geyer has a B.S. in microbiology from the University of Southwestern Louisiana and an M.S. in microbiology from Texas A&M University.

Cynthia Porter

Head of Development Operations

Cynthia has over 30 years of clinical operations, project and portfolio management. Her experience encompasses ophthalmology, oncology, and immunology among other indications. Cynthia has various leadership positions at Roche, Genentech and AbbVie. Cynthia led the Lucentis clinical operations team through Phase 3. She has a B.S.N. from the University of Northern Colorado and an M.B.A from City University.